Market Cap | 5.02B | P/E | - | EPS this Y | 47.90% | Ern Qtrly Grth | - |
Income | -292.12M | Forward P/E | -15.92 | EPS next Y | 39.10% | 50D Avg Chg | -10.00% |
Sales | 1.36B | PEG | - | EPS past 5Y | - | 200D Avg Chg | -6.00% |
Dividend | N/A | Price/Book | 7.65 | EPS next 5Y | - | 52W High Chg | -26.00% |
Recommedations | 1.70 | Quick Ratio | 3.89 | Shares Outstanding | 123.68M | 52W Low Chg | 29.00% |
Insider Own | 3.70% | ROA | -14.18% | Shares Float | 119.14M | Beta | 1.53 |
Inst Own | 98.67% | ROE | -40.78% | Shares Shorted/Prior | 7.58M/7.62M | Price | 43.93 |
Gross Margin | 53.85% | Profit Margin | -21.47% | Avg. Volume | 977,151 | Target Price | 130.83 |
Oper. Margin | -10.62% | Earnings Date | Nov 6 | Volume | 880,597 | Change | -3.15% |
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
Piper Sandler | Overweight | Sep 13, 24 |
Canaccord Genuity | Buy | Aug 27, 24 |
Morgan Stanley | Overweight | Aug 13, 24 |
Piper Sandler | Overweight | Aug 13, 24 |
TD Cowen | Buy | Aug 9, 24 |
BTIG | Buy | Aug 9, 24 |
Stephens & Co. | Overweight | Aug 9, 24 |
UBS | Buy | Aug 9, 24 |
Baird | Outperform | Aug 9, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Brophy Michael Burkes | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Feb 01 | Sell | 67.7295 | 22,281 | 1,509,081 | 70,646 | 02/02/24 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Jan 26 | Sell | 65.09 | 3,235 | 210,566 | 92,927 | 01/30/24 |
Sheena Jonathan | - - | Jan 26 | Sell | 65.09 | 546 | 35,539 | 478,585 | 01/30/24 |
RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER | Jan 26 | Sell | 65.09 | 4,265 | 277,609 | 204,218 | 01/30/24 |
Chapman Steven Leonard | CEO AND PRESIDENT CEO AND PRESIDENT | Jan 26 | Sell | 65.09 | 14,813 | 964,178 | 246,957 | 01/30/24 |
Moshkevich Solomon | PRESIDENT, CLINICALD.. PRESIDENT, CLINICALDIAGNOSTICS | Jan 29 | Sell | 65.09 | 3,426 | 222,998 | 194,977 | 01/30/24 |
Fesko John | PRESIDENT, CHIEF BUS.. PRESIDENT, CHIEF BUS. OFFICER | Jan 26 | Sell | 65.09 | 2,358 | 153,482 | 108,494 | 01/30/24 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Jan 24 | Sell | 67 | 944 | 63,248 | 64,810 | 01/26/24 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Jan 20 | Sell | 66.89 | 2,973 | 198,864 | 65,754 | 01/23/24 |
Sheena Jonathan | - - | Jan 20 | Sell | 68.16 | 351 | 23,924 | 469,726 | 01/23/24 |
Chapman Steven Leonard | CEO AND PRESIDENT CEO AND PRESIDENT | Jan 20 | Sell | 68.16 | 1,958 | 133,457 | 175,550 | 01/23/24 |
RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER | Jan 20 | Sell | 68.16 | 892 | 60,799 | 181,050 | 01/23/24 |
Sheena Jonathan | - - | Jan 03 | Sell | 60.48 | 6,000 | 362,880 | 21,155 | 01/05/24 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Dec 27 | Sell | 62.79 | 2,292 | 143,915 | 64,810 | 12/29/23 |
Chapman Steven Leonard | CEO AND PRESIDENT CEO AND PRESIDENT | Dec 27 | Sell | 63.29 | 2,604 | 164,807 | 172,348 | 12/29/23 |
Chapman Steven Leonard | CEO AND PRESIDENT CEO AND PRESIDENT | Sep 23 | Sell | 45.2972 | 1,674 | 75,828 | 71,438 | 12/29/23 |
Sheena Jonathan | - - | Dec 27 | Sell | 62.4 | 1,447 | 90,293 | 21,655 | 12/29/23 |
RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER | Dec 27 | Sell | 63.29 | 728 | 46,075 | 180,442 | 12/29/23 |
Marcus Gail Boxer | Director Director | Dec 08 | Sell | 57.52 | 500 | 28,760 | 20,146 | 12/12/23 |
Sheena Jonathan | - - | Dec 06 | Sell | 58.52 | 5,000 | 292,600 | 474,743 | 12/08/23 |
Chapman Rowan E | Director Director | Nov 29 | Sell | 55.9714 | 1,998 | 111,831 | 9,373 | 12/01/23 |
Marcus Gail Boxer | Director Director | Nov 21 | Sell | 54.3136 | 1,000 | 54,314 | 20,646 | 11/22/23 |
Chapman Steven Leonard | CEO AND PRESIDENT CEO AND PRESIDENT | Nov 20 | Sell | 55 | 2,566 | 141,130 | 217,554 | 11/22/23 |
Sheena Jonathan | - - | Nov 02 | Sell | 40.31 | 6,000 | 241,860 | 22,155 | 11/03/23 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Oct 20 | Sell | 40.55 | 3,940 | 159,767 | 64,810 | 10/24/23 |
Chapman Steven Leonard | CEO AND PRESIDENT CEO AND PRESIDENT | Oct 20 | Sell | 40.39 | 2,595 | 104,812 | 220,120 | 10/24/23 |
Sheena Jonathan | - - | Oct 20 | Sell | 40.14 | 1,335 | 53,587 | 22,655 | 10/24/23 |
RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER | Oct 20 | Sell | 40.39 | 803 | 32,433 | 179,807 | 10/24/23 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Sep 27 | Sell | 45.9 | 2,291 | 105,157 | 64,833 | 09/29/23 |
Chapman Steven Leonard | CEO AND PRESIDENT CEO AND PRESIDENT | Sep 27 | Sell | 45.82 | 2,617 | 119,911 | 217,554 | 09/29/23 |
RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER | Sep 27 | Sell | 45.82 | 732 | 33,540 | 179,110 | 09/29/23 |
Sheena Jonathan | - - | Sep 27 | Sell | 45.94 | 5,448 | 250,281 | 484,745 | 09/29/23 |
Sheena Jonathan | - - | Sep 06 | Sell | 59.26 | 6,000 | 355,560 | 23,155 | 09/08/23 |
Sheena Jonathan | - - | Sep 01 | Sell | 60.0062 | 10,000 | 600,062 | 494,746 | 09/01/23 |
Chapman Steven Leonard | CEO AND PRESIDENT CEO AND PRESIDENT | Aug 11 | Sell | 55 | 2,578 | 141,790 | 214,988 | 08/14/23 |
Sheena Jonathan | - - | Aug 02 | Sell | 44.17 | 6,000 | 265,020 | 504,746 | 08/04/23 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Jul 25 | Sell | 46.58 | 2,347 | 109,323 | 64,833 | 07/27/23 |
RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER | Jul 20 | Sell | 47.83 | 800 | 38,264 | 178,478 | 07/24/23 |
Sheena Jonathan | - - | Jul 20 | Sell | 47.63 | 1,333 | 63,491 | 509,746 | 07/24/23 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Jul 20 | Sell | 47.83 | 1,570 | 75,093 | 67,180 | 07/24/23 |
Chapman Steven Leonard | CEO AND PRESIDENT CEO AND PRESIDENT | Jul 20 | Sell | 47.83 | 2,578 | 123,306 | 217,566 | 07/24/23 |
Brophy Michael Burkes | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Apr 25 | Sell | 50.99 | 4,656 | 237,409 | 64,833 | 06/29/23 |
Chapman Steven Leonard | CEO AND PRESIDENT CEO AND PRESIDENT | Jun 27 | Sell | 50.88 | 2,605 | 132,542 | 214,983 | 06/29/23 |
RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER | Jun 27 | Sell | 50.88 | 728 | 37,041 | 177,778 | 06/29/23 |
Sheena Jonathan | - - | Jun 27 | Sell | 50.85 | 5,447 | 276,980 | 509,746 | 06/29/23 |
Chapman Rowan E | Director Director | Jun 13 | Sell | 50.5750 | 1,767 | 89,366 | 8,621 | 06/15/23 |
Sheena Jonathan | - - | Jun 07 | Sell | 48.93 | 6,000 | 293,580 | 24,655 | 06/09/23 |
Sheena Jonathan | - - | May 10 | Sell | 54.11 | 5,000 | 270,550 | 519,746 | 05/12/23 |
Sheena Jonathan | - - | Apr 20 | Sell | 54.49 | 333 | 18,145 | 524,746 | 04/24/23 |
RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL.. SEC. AND CHIEF LEGAL OFFICER | Apr 20 | Sell | 54.63 | 796 | 43,485 | 177,143 | 04/24/23 |